Clinical Trials Directory

Trials / Unknown

UnknownNCT04154228

Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
Tel-Aviv Sourasky Medical Center · Other Government
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Not accepted

Summary

18F-FDG PET/MR imaging protocol integrating advanced MR vascular imaging sequences, along with computerized quantitative methods for data analysis, is expected to serve as an objective tool for assessment of lymphoma patients. The aim of this prospective study is to develop an automatic artificial intelligence-based tool for the assessment of early response to treatment and evaluation of residual masses in patients with lymphoma. Specific objectives are: 1. To evaluate the added value of 18F-FDG PET/MRI compared with PET/CT in imaging lymphoma. 2. To optimize PET/MR imaging protocol for lymphoma assessment. 3. To develop an automated tool for staging patients with lymphoma. 4. To develop an automated method for early prediction of response to therapy and prognosis in patients with lymphoma. 5. To develop an automated non-invasive tool for discriminating benign from active residual masses at end of treatment in patients with lymphoma.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTPET/MR scanPatients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed. PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI).

Timeline

Start date
2019-12-10
Primary completion
2020-01-10
Completion
2021-12-10
First posted
2019-11-06
Last updated
2019-11-06

Source: ClinicalTrials.gov record NCT04154228. Inclusion in this directory is not an endorsement.